Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate.
- Citation data:
BMC pharmacology & toxicology, ISSN: 2050-6511, Vol: 14, Issue: 1, Page: 7
- Publication Year:
- Repository URL:
- ClinicalTrials.gov Identifier:
- Pharmacology, Toxicology and Pharmaceutics; Medicine; Angiogenesis; Neovascularization; Ocular pharmacology; Retinal degeneration; Combretastatin A-4 Phosphate; CA4P; Vascular disrupting agents; VDA; Ophthalmology
This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P in patients with neovascular age-related macular degeneration (AMD).